DPT Enhances Flexibility and Efficiencies at San Antonio Facility
News Jul 09, 2015
DPT Laboratories has implemented a new order execution strategy that will enhance operations at its San Antonio facility.
The new strategy entails a realignment and augmentation of resources to support three critical areas at DPT: 1) high-speed bottle production, 2) aerosols/foams filling and packaging, and 3) traditional semi-solids and liquids production.
One of three DPT Centers of Excellence, the San Antonio facility was purpose-built to support semi-solid and liquid development and manufacturing solutions. This new strategy represents the next step for the company’s existing operational platform.
“We focused on prioritizing the technical expertise and resources we already have, adding new resources where necessary to create more specialized work centers,” said Lyle Flom, vice president and general manager of DPT’s San Antonio Site Operations. “With these structural changes, our teams will be able to focus their technical expertise to improve operational efficiencies and enhance our already strong quality record at this site. This is an evolution of our Center of Excellence strategy in the semi-solid and liquid space and supports our strategic commitment to continuously improve our manufacturing execution and regulatory/compliance environments.”
Current clients can expect to see DPT’s continued focus on quality. “A big component of this strategy was centered on preparing for the future,” said Flom. “We’re focusing on maximizing quality, capacity and resource utilization to add versatility to our offerings, while also driving productivity and efficiency.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE